China vs FDA (USA)
This page provides a plain English comparison of china vs fda (usa) from the perspective of China's NMPA regulatory framework. Full content to be completed during editorial review.
Why this comparison matters
Understanding how China's requirements differ from other major frameworks helps manufacturers:
- Identify data gaps early
- Sequence submissions efficiently
- Re-use clinical and technical data across markets
- Avoid surprises from China-unique requirements (e.g. China Agent, 5-year re-registration, clinical trial exemption list)
See also: Multi-Market Strategy
Disclaimer
Content on this site is written with AI assistance and is intended as a navigation aid only. Always verify against official NMPA sources before making regulatory decisions. Not affiliated with NMPA or any Chinese Government body. Not legal or regulatory advice.